Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
CVT-301
print preview
bookmark
share with colleague
General Information
Company
Civitas Therapeutics Inc.
Description
Inhaled formulation of levodopa delivered via Civitas' ARCUS inhalation technology
Molecular Target
Mechanism of Action
Latest Stage of Development
Phase II
Indication
Parkinson's disease (PD)
Partner
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy
General Information